$0.16
(1.23%)
Add to watchlist
Create an alert
Stocks and Shares ISAXencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Company Information
About this company
Key people
Bassil I. Dahiyat
President, Chief Executive Officer, Founder and Director
Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
John R. Desjarlais
Executive Vice President - Research, Chief Scientific Officer
Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
A. Bruce Montgomery
Lead Independent Director
Raymond J. Deshaies
Director
Ellen Gwen Feigal
Independent Director
Kevin C. Gorman
Independent Director
Kurt A. Gustafson
Independent Director
Click to see more
Key facts
- Shares in issue71.41m
- EPICXNCR
- ISINUS98401F1057
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$912.63m
- Employees250
- ExchangeNASDAQ
- IndexS&P 600 Small Cap
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.